Radiopharm Theranostics (ASX:RAD) partnered with Nasdaq-listed Lantheus to develop oncology radiopharmaceuticals in Australia, according to a Monday filing with the Australian bourse.
The partnership will see the company lead clinical development efforts, with Lantheus covering costs associated with the program, the filing said.
The company will receive up to $2 million in milestone payments for achieving key clinical development objectives, such as ethics committee approval, first patient dosing, and patient enrollment for the first imaging trial, according to the filing.
Radiopharm Theranostics shares rose nearly 9% in morning trade Tuesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。